C069P: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by brolucizumab.EK000142-EK0575: Human EG-VEGF ELISA Kit
Range 15.6pg/ml-1000pg/ml
Sensitivity < 1pg/ml
Specificity: no detectable cross-reactivity with any other cytokine.
Application: for quantitative detection of human EG-VEGF in serum, plasma, or cell culture supernates.
Expiration: four months at 4°C and eight months at -20°C.BP002885-PRO-248: Recombinant Human Endostatin Protein
Source: E. coli-derived.
The activity calculated by ECE migration inhibition was found to be 50,000 IU/mg.
Purity: > 98.0% as determined by RP-HPLC and SDS-PAGE.PA005226-ANT-313: PEDF Monoclonal Antibody
Mouse Monoclonal Antibody;
Applications: WB, ELISA;
Reactivity: Human;
Clone: P1C4AT;
Isotype: Mouse IgG1.BP000027-GD1: Recombinant Human VEGF165 (aa 27-191) Protein
Source: HEK 293 cell-derived.
The VEGF activity is measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 1-5 ng/ml.
Endotoxin: < 1.0 EU per ug of the protein by the LAL method.
Purity: > 95% by SDS-PAGE under reducing conditions.BP000027-CYT-200: Recombinant Human VEGF (121 a.a.) Protein, Sf9
Source: Sf9, Insect Cells-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 2-5 ug/ml corresponding to a Specific Activity of 200,000-500,000 IU/mg.
Purity: >90% by SDS-PAGE and RP-HPLC.BP000027-CYT-225: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein, HEK
Source: HEK 293 (Human Embryonic Kidney cell line)-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-6 ug/ml corresponding to a Specific Activity of 166,667-1,000,000 IU/mg.
Purity: > 95% by SDS-PAGE.BP000027-CYT-226: Recombinant Mouse Vascular Endothelial Growth Factor (VEGF) Protein, Sf9
Source: Baculovirus Sf9 cells-derived.
The ED50 range, determined by the dose-dependent proliferation of human umbilical vein endothelial cells (HUVEC) (measured by 3H-thymidine uptake) is 1-2 ug/ml, corresponding to a specific activity of 1x106 Units/mg.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000027-CYT-241: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein
Source: E. coli-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-8 ug/ml corresponding to a Specific Activity of 125,000-1,000,000 IU/mg.
Purity: > 98% by SDS-PAGE and RP-HPLC.BP000027-CYT-260: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein, CHO
Source: Chinese Hamster Ovarian Cell-derived.
Determined by its ability to stimulate 3H-Thymidine incorporation in human ublical vein endothelial cells, the ED50 for this effect was found to be 2-6 ng/ml corresponding to a Specific Activity of 166,667-500,000 IU/mg.
Purity: > 97% by SDS-PAGE and RP-HPLC.